Literature DB >> 31903600

Randomized clinical trial of continuous transversus abdominis plane block, epidural or patient-controlled analgesia for patients undergoing laparoscopic colorectal cancer surgery.

Y J Xu1, X Sun1, H Jiang1, Y H Yin1, M L Weng1, Z R Sun1, W K Chen1, C H Miao1.   

Abstract

BACKGROUND: The optimal analgesia regimen after laparoscopic colorectal cancer surgery is unclear. The aim of the study was to characterize the beneficial effects of continuous transversus abdominis plane (TAP) blocks initiated before operation on outcomes following laparoscopic colorectal cancer surgery.
METHODS: Patients undergoing surgery for colorectal cancer were divided randomly into three groups: combined general-TAP anaesthesia (TAP group), combined general-thoracic epidural anaesthesia (TEA group) and standard general anaesthesia (GA group). The primary endpoint was duration of hospital stay. Secondary endpoints included gastrointestinal motility, pain scores and plasma levels of cytokines.
RESULTS: In total, 180 patients were randomized and 165 completed the trial. The intention-to-treat analysis showed that duration of hospital stay was significantly longer in the TEA group than in the TAP and GA groups (median 4·1 (95 per cent c.i. 3·8 to 4·3) versus 3·1 (3·0 to 3·3) and versus 3·3 (3·2 to 3·6) days respectively; both P < 0·001). Time to first flatus was earlier in the TAP group (P < 0·001). Visual analogue scale (VAS) scores during coughing were lower in the TAP and TEA groups than the GA group (P < 0·001). Raised plasma levels of vascular endothelial growth factor C, interleukin 6, adrenaline and cortisol were attenuated significantly by continuous TAP block.
CONCLUSION: Continuous TAP analgesia not only improved gastrointestinal motility but also shortened duration of hospital stay. A decreased opioid requirement and attenuating surgical stress response may be potential mechanisms. Registration number: ChiCTR-TRC-1800015535 ( http://www.chictr.org.cn).
© 2020 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2020        PMID: 31903600     DOI: 10.1002/bjs.11403

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  6 in total

1.  Transversus abdominis plane block versus thoracic epidural analgesia in colorectal surgery: a systematic review and meta-analysis.

Authors:  Hytham K S Hamid; Artur Marc-Hernández; Alan A Saber
Journal:  Langenbecks Arch Surg       Date:  2020-09-24       Impact factor: 3.445

2.  Purely ropivacaine-based TEA vs single TAP block in pain management after elective laparoscopic colon surgery within an upgraded institutional ERAS program.

Authors:  Vilma Bumblyte; Suvi K Rasilainen; Anu Ehrlich; Tom Scheinin; Vesa K Kontinen; Aino Sevon; Heikki Vääräniemi; Alexey A Schramko
Journal:  Surg Endosc       Date:  2021-09-03       Impact factor: 4.584

3.  The additional analgesic effects of transverse abdominis plane block in patients receiving low-dose intrathecal morphine for minimally invasive colorectal surgery: a randomized, single-blinded study.

Authors:  Seung-Rim Han; Chul Seung Lee; Jung Hoon Bae; Hyo Jin Lee; Mi Ran Yoon; Do Sang Lee; Yoon Suk Lee; Abdullah Al-Sawat; Jung-Woo Shim; Sang-Hyun Hong; In Kyu Lee
Journal:  Ann Surg Treat Res       Date:  2021-10-01       Impact factor: 1.859

4.  Transversus Abdominis Plane Block in Colorectal Surgery: A Meta-Analysis.

Authors:  Dmitriy Viderman; Mina Aubakirova; Yerkin G Abdildin
Journal:  Front Med (Lausanne)       Date:  2022-02-23

5.  Effects of Abdominal Wall Blocks on Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Surgery: A Randomized Controlled Study.

Authors:  Tianlin Liu; Jingtang Tuo; Qianjie Wei; Xiuwei Sun; Haochen Zhao; Xiaochen Zhao; Min Qu
Journal:  Med Sci Monit       Date:  2022-03-14

6.  Epidural analgesia and postoperative complications in colorectal cancer surgery. An observational registry-based study.

Authors:  Rune P Hasselager; Jesper Hallas; Ismail Gögenur
Journal:  Acta Anaesthesiol Scand       Date:  2022-06-27       Impact factor: 2.274

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.